The integration of cancer biomarkers into oncology has revolutionized cancer treatment,
yielding remarkable advancements in cancer therapeutics and the prognosis of cancer …

The development of targeted therapy in epidermal growth factor receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC) patients has radically changed their clinical …

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC …

Non-small cell lung cancer (NSCLC) is largely promoted by a multistep tumorigenesis
process involving various genetic and epigenetic alterations, which essentially contribute to …

Development of effective strategies to manage the inevitable acquired resistance to
osimertinib, a third-generation EGFR inhibitor for the treatment of EGFR-mutant (EGFRm) …

Objectives Osimertinib is a standard treatment for patients with EGFR-mutant non-small cell
lung cancer (NSCLC) and is highly effective for brain metastases (BMs). However, it is …

Targeted therapy has improved prognoses for patients with advanced non–small-cell lung
cancer (NSCLC) that has epidermal growth factor receptor (EGFR) mutations. The seminal …

EGFR tyrosine kinase inhibitors (TKIs) are effective against EGFR-mutated lung cancer, but
tumors eventually develop resistance to these drugs. Although TP53 gain-of-function (GOF) …

Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …